Background Breast cancer susceptibility may be modulated partly through polymorphisms in oxidative enzymes, one of which is myeloperoxidase (MPO). Association of the low transcription activity variant allele A in the G463A polymorphism has been investigated for its association with breast cancer risk, considering the modifying effects of menopausal status and antioxidant intake levels of cases and controls. Methodology/Principal Findings To obtain a more precise estimate of association using the odds ratio (OR), we performed a meta-analysis of 2,975 cases and 3,427 controls from three published articles of Caucasian populations living in the United States. Heterogeneity among studies was tested and sensitivity analysis was applied. The lower transcriptional activity AA genotype of MPO in the pre-menopausal population showed significantly reduced risk (OR 0.56–0.57, p = 0.03) in contrast to their post-menopausal counterparts which showed non-significant increased risk (OR 1.14; p = 0.34–0.36). High intake of antioxidants (OR 0.67–0.86, p = 0.04–0.05) and carotenoids (OR 0.68–0.86, p = 0.03–0.05) conferred significant protection in the women. Stratified by menopausal status, this effect was observed in pre-menopausal women especially those whose antioxidant intake was high (OR 0.42–0.69, p = 0.04). In post-menopausal women, effect of low intake elicited susceptibility (OR 1.19–1.67, p = 0.07–0.17) to breast cancer. Conclusions/Significance Based on a homogeneous Caucasian population, the MPO G463A polymorphism places post-menopausal women at risk for breast cancer, where this effect is modified by diet.
References
[1]
Bundred NJ, Dover MS, Aluwihare N, Faragher EB, Morrison JM (1993) Smoking and periductal mastitis. Bmj 307: 772–773.
[2]
Josephy PD (1996) The role of peroxidase-catalyzed activation of aromatic amines in breast cancer. Mutagenesis 11: 3–7.
[3]
Samoszuk MK, Nguyen V, Gluzman I, Pham JH (1996) Occult deposition of eosinophil peroxidase in a subset of human breast carcinomas. Am J Pathol 148: 701–706.
[4]
Williams JA, Stone EM, Millar BC, Hewer A, Phillips DH (2000) Pathways of heterocyclic amine activation in the breast: DNA adducts of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) formed by peroxidases and in human mammary epithelial cells and fibroblasts. Mutagenesis 15: 149–154.
[5]
Eriksson NE, Holmen A, Hogstedt B, Mikoczy Z, Hagmar L (1995) A prospective study of cancer incidence in a cohort examined for allergy. Allergy 50: 718–722.
[6]
Smith-Warner SA, Spiegelman D, Yaun SS, Adami HO, Beeson WL, et al. (2001) Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. Jama 285: 769–776.
[7]
Gaudet MM, Britton JA, Kabat GC, Steck-Scott S, Eng SM, et al. (2004) Fruits, vegetables, and micronutrients in relation to breast cancer modified by menopause and hormone receptor status. Cancer Epidemiol Biomarkers Prev 13: 1485–1494.
[8]
Bekesi G, Kakucs R, Varbiro S, Feher J, Pazmany T, et al. (2001) Induced myeloperoxidase activity and related superoxide inhibition during hormone replacement therapy. Bjog 108: 474–481.
[9]
Li Y, Ambrosone CB, McCullough MJ, Ahn J, Stevens VL, et al. (2009) Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk. Carcinogenesis 30: 777–784.
[10]
Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, et al. (1996) An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271: 14412–14420.
[11]
Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, et al. (1997) Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 78: 97–107.
[12]
Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, et al. (1999) Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 155: 31–41.
[13]
London SJ, Lehman TA, Taylor JA (1997) Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 57: 5001–5003.
[14]
Schabath MB, Spitz MR, Hong WK, Delclos GL, Reynolds WF, et al. (2002) A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer 37: 35–40.
[15]
Van Schooten FJ, Boots AW, Knaapen AM, Godschalk RW, Maas LM, et al. (2004) Myeloperoxidase (MPO) -463G->A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev 13: 828–833.
[16]
Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA (2001) A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142: 336–339.
[17]
Saygili EI, Aksoy N, Pehlivan M, Sever T, Yilmaz M, et al. (2009) Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma. Leuk Lymphoma 50: 2030–2037.
[18]
Li D, Diao Y, Li H, Fang X, Li H (2008) Association of the polymorphisms of MTHFR C677T, VDR C352T, and MPO G463A with risk for esophageal squamous cell dysplasia and carcinoma. Arch Med Res 39: 594–600.
[19]
Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, et al. (2002) Point: myeloperoxidase -463G？>a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 11: 1550–1554.
[20]
Le Marchand L, Seifried A, Lum A, Wilkens LR (2000) Association of the myeloperoxidase -463G？>a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 9: 181–184.
[21]
Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, et al. (2001) Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett 164: 161–167.
[22]
Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, et al. (2004) Myeloperoxidase genotype, fruit and vegetable consumption, and breast cancer risk. Cancer Res 64: 7634–7639.
[23]
Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, et al. (2009) Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol 27: 4973–4979.
[24]
He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J (2009) A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat 113: 585–594.
[25]
Yang J, Ambrosone CB, Hong CC, Ahn J, Rodriguez C, et al. (2007) Relationships between polymorphisms in NOS3 and MPO genes, cigarette smoking and risk of post-menopausal breast cancer. Carcinogenesis 28: 1247–1253.
[26]
Lin SC, Chou YC, Wu MH, Wu CC, Lin WY, et al. (2005) Genetic variants of myeloperoxidase and catechol-O-methyltransferase and breast cancer risk. Eur J Cancer Prev 14: 257–261.
[27]
Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2005) The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 34: 1319–1328.
[28]
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
[29]
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
[30]
Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820–826.
[31]
Berman NG, Parker RA (2002) Meta-analysis: neither quick nor easy. BMC Med Res Methodol 2: 10.
[32]
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
[33]
Ioannidis JP, Trikalinos TA (2007) The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. Cmaj 176: 1091–1096.
[34]
Reynolds W (2003) Gender dependent association of the -463G/A myeloperoxidase polymorphism with impaired vasodilation in CAD patients [PhD]. San Diego: University of California.
[35]
Roy D, Cai Q, Felty Q, Narayan S (2007) Estrogen-induced generation of reactive oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev 10: 235–257.
[36]
Kumar AP, Piedrafita FJ, Reynolds WF (2004) Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem 279: 8300–8315.
[37]
Marcozzi FG, Madia F, Del Bianco G, Mattei E, de Feo G (2000) Lacrimal fluid peroxidase activity during the menstrual cycle. Curr Eye Res 20: 178–182.
[38]
Chu H, Wang M, Wang M, Gu D, Wu D, et al. (2010) The MPO -463G>A polymorphism and cancer risk: a meta-analysis based on 43 case-control studies. Mutagenesis 25: 389–395.
[39]
Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, et al. (2005) Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 65: 1105–1111.
